El interés en corto de CytomX Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de CytomX Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

CytomX Therapeutics (NASDAQ:CTMX) Bolsa, Informe de interés en corto

CytomX Therapeutics

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

Needham analyst Quinn Bolton maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Buy and lowers the price target from $95 to $90.

News

Price Target

Analyst Ratings

SYNA

Needham Maintains Buy on Synaptics, Lowers Price Target to $90

Barclays analyst Kannan Venkateshwar maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Equal-Weight and raises the price target from $8 to $10.

Barclays Maintains Equal-Weight on Warner Bros. Discovery, Raises Price Target to $10

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

Reiteration

MLTX

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Crypto analysts are seeing signals that Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) may soon rally against Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), potentially <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40255976/is-ethereum-going-to-keep-underperforming-bitcoin-heres-what-technical-analysis-says">reversing recent underperformance</a>.
What Happened: According to Lookonchain, a major Ethereum whale with holdings of 398,891 ETH ($1.14 billion) recently sold 29,897 ETH at $2,839 for a profit of $84.7 million (810x return), <a href="https://x.com/lookonchain/status/1854735745099219430">signaling</a> confidence among some high-stake investors in ETH&#8217;s future trajectory. He continues to hold 368,992 ETH ($1.07 billion).
Ethereum has rallied 17% over the past seven days, prompting bullish forecasts from traders and analysts:
<ul>
<li>Crypto trader &#8220;Astronomer&#8221; swapped half of his BTC for ETH, calling it "the meme trade of the year." He points out that while BTC is up 30%, ETH has risen only 10% but predicts Ethereum's rally will follow, targeting a 70% increase in ETH/BTC. He <a href="https://x.com/astronomer_zero/status/1854418883140296828">added</a>, "Now that the majority of the BTC dominated move of this breakout leg is taking place, it just comes down to catch the ETH dominated move next."</li>
<li>Analyst Benjamin Cowen <a href="https://x.com/intocryptoverse/status/1854259773144981768">offered</a> a measured take, noting, "If ETH can break its bull market support on weekly closes, my position might change." He continues to hedge cautiously with the ETH/BTC ratio at 0.035.</li>
<li>Adding to the discussion, Michaël van de Poppe <a href="https://x.com/CryptoMichNL/status/1854441159583785087">observes</a>, "The markets are rotating, as ETH has a massive bounce upwards." He suggests that if ETH can establish a higher low, it could continue its upward momentum.</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a>
Why It Matters: This mix of bullish and cautious viewpoints reflects the complex nature of crypto market behaviour, with some analysts seeing Ethereum poised for significant gains. Investors are advised to consider diverse perspectives as the market remains highly volatile.
IntoTheBlock data shows large transaction volume for Ethereum decreased by 0.7% with active addresses up 7.4% and high-value transactions falling from 7,274 to 7,648. Net exchange flows, however, are up by 2,155.7%.
Despite an underperformance of ETH against BTC over the past month, 74% of holders are still making a profit.
What&#8217;s Next: The influence of <a href="https://www.benzinga.com/money/is-ethereum-a-good-investment" target="_blank" rel="noreferrer noopener">Ethereum as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41796743/ethereum-whales-wake-up-from-slumber-to-cash-out-90m-amid-rally-but-indicators-show-sentim">Ethereum Whales Wake Up From Slumber To Cash Out $90M Amid Rally, But Indicators Show Sentiment Can Flip</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Ethereum Up 17% On The Week: What Is Going On?

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and lowers the price target from $45 to $41.

RNAC

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $41

Ciena's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) short percent of float has risen 3.56% since its last report. The company recently reported that it has 6.11 million shares sold short, which is 5.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ciena Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093400_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ciena has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ciena's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ciena's peer group average for short interest as a percentage of float is 7.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CIEN

Peering Into Ciena's Recent Short Interest

Kraft Heinz's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NYSE">KHC</a>) short percent of float has fallen 3.77% since its last report. The company recently reported that it has 33.76 million shares sold short, which is 3.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kraft Heinz Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093395_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kraft Heinz has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Kraft Heinz's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kraft Heinz's peer group average for short interest as a percentage of float is 4.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Kraft Heinz's Recent Short Interest

Cheniere Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) short percent of float has risen 7.09% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 1.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cheniere Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093389_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cheniere Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cheniere Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cheniere Energy's peer group average for short interest as a percentage of float is 3.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cheniere Energy's Recent Short Interest

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $240 to $260.

VEEV

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $260

HC Wainwright &amp; Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy and maintains $40 price target.

OKUR

HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $40 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and lowers the price target from $6 to $5.

RLYB

HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $5

<a href="https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales">https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales</a>
&nbsp;
Toyota Motor Corp.'s North American chief operating officer criticized the US's policies promoting speedy adoption of electric vehicles, calling them "de facto mandates" out of sync with consumer demand.

Management

Global

'Toyota Executive Lashes Out At U.S. Regulations Promoting EV Sales' - Bloomberg News

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and raises the price target from $27 to $39.

CARG

Needham Maintains Buy on CarGurus, Raises Price Target to $39

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $50 to $57.

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Barclays analyst Jared Shaw maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and raises the price target from $56 to $64.

Barclays Maintains Overweight on Synovus Finl, Raises Price Target to $64

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/MSI/earnings">FY24 adjusted EPS guidance above estimates on Thursday.</a>
Motorola Solutions reported quarterly earnings of $3.74 per share which beat the analyst consensus estimate of $3.38 per share. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.76 billion.
&#8220;Our third-quarter results were exceptional, with record Q3 revenue, earnings and cash flow,&#8221; said Greg Brown, chairman and CEO, Motorola Solutions. &#8220;We achieved strong growth across the board, and I&#8217;m pleased with the momentum of our business. As a result, we&#8217;re again raising our revenue and earnings expectations for the full year.&#8221;
Motorola Solutions shares gained 6.8% to trade at $501.80 on Friday.
These analysts made changes to their price targets on Motorola Solutions following earnings announcement.
<ul>
<li>Raymond James analyst Adam Tindle maintained Motorola with an Outperform and raised the price target from $425 to $515.</li>
<li>Barclays analyst Tim Long maintained the stock with an Overweight and raised the price target from $467 to $529.</li>
</ul>
Considering buying MSI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png" alt="" class="wp-image-638367" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Markets

These Analysts Raise Their Forecasts On Motorola Solutions Following Q3 Earnings

HC Wainwright &amp; Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) with a Buy and maintains $13 price target.

TNGX

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Underweight and raises the price target from $245 to $255.

Barclays Maintains Underweight on Rockwell Automation, Raises Price Target to $255

WIIM

Canopy Growth shares are trading lower. The company reported Q2 financial results.

Warning: CTMX is at high risk of performing badly

CytomX Q3 2024 Earnings Preview

Reports Q3 revenue $33.43M, consensus $17.61M. "We are encouraged by the progress during Q3 across our clinical pipeline including the ongoing Phas...

CytomX Therapeutics reports Q3 EPS 7c, consensus (17c)

CytomX Therapeutics Inc. ( ($CTMX) ) has released its Q3 earnings. Here is a breakdown of the information CytomX Therapeutics Inc. presented to its...

CytomX Therapeutics Reports Q3 Progress and Growth

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Piper Sandler lowered the firm's price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares follow...

CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler

CTMX

Opinion

Press Releases

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Health Care

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

BNTX

FGEN

ONCY

TSX:ONC

VSTM

Agenus

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

bluebird bio

BeyondSpring

Celularity

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chimerix

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

IO Biotech

MAIA Biotechnology

Metagenomi

MediciNova

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Vistagen Therapeutics, Inc. - Common Stock

Comments

CytomX Therapeutics

Interés en corto

CytomX Therapeutics (NASDAQ:CTMX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL